Copy Link
ISPOR Europe was the busiest we’ve ever seen it. Those few days were jam-packed with engaging plenary sessions, educational symposia, poster research, and networking opportunities. Many fruitful conversations were had, with the team contributing the following rundown list of 9 main takeaways from the conference.
1. Real-world evidence (RWE) supporting innovative treatments
Mark spoke at the panel symposium on “How can we shape HTA with real-world evidence to encourage rare disease innovation?”. The group discussed the complementary relationship between RWE and clinical studies and the various applications of RWE, but equally situations in which real-world data (RWD) is difficult to acquire. Mark (above, presenting)
2. Innovative ways of capturing data
Taking a step back from typical app input and going for SMS. Our research poster on the use of SMS surveys in real-world studies was an interesting talking point with great engagement (both in the study and in the conference!) [see the full poster here] Sam (above)
3. EU Joint Clinical Assessment (JCA)
A hot topic which will undoubtedly reappear next year as this regulation is being phased in from 2025. We looked at the scientific considerations related to shared Patient/Population, Intervention, Comparison, and Outcomes (PICOs) for these evaluations. We’re eager to see how this will impact the current landscape of health technology assessment (HTA) in the EU, including its implication in evidence generation. Anna (above, left)
4. Artificial Intelligence (AI) in health economics and outcomes research (HEOR)
Exploring the expanding role of AI in shaping the future of HEOR. It was impressive to see how extensively AI is already being applied! Mark
5. Regulatory use cases of RWE:
Gaining insights into the growing use of RWE by the European Medicines Agency (EMA) and its impact on regulatory decisions and innovation. Amber (above, left)
6. Country-specific chapters
ISPOR encourages nuanced conversations in native languages, facilitating a deeper understanding of regional challenges and accelerating progress towards equitable access to medicine. I loved being part of the ISPOR Turkey Chapter. Selcan (above, third from left)
7. Patient-centered outcomes discussions
Seeing more conversation on PCO studies, pediatric utilities, patient Delphi panels, trial interviews, vignette studies, health utility and preference studies, and more. It was a real pleasure to see how we can foster genuine patient engagement in research. Akosua (above, right)
8. External Comparator Arms – RWE
Understand the significance of using external comparator arms in RWE-based methodologies, especially for diseases where traditional clinical trials face ethical or feasibility challenges. Octavia (left)
9. And with that… a bigger focus on patient centricity
This was a real focus point this year and I witnessed this in person at the great turnout for my poster tour on patient-centered research. It’s brilliant to see this moving in the right direction, but we would like to see more patients and caregivers at ISPOR, particularly to speak on panels on patient-centered research. Only 7 patients were awarded travel grants this year. Let’s do better next year as an industry and bring more patient voices to the table! Sam
If you would like to catch up with any of the Vitaccess team who attended ISPOR, get in touch today at info@vitaccess.com.
Attending team and blog authors
Mark Larkin, CEO
Amber Kudlac, Director, Analytics
Sam Llewellyn, Associate Director
Anna Richards, Head of Commercial
Akosua Ofori , Associate Consultant
Octavia Borecka, Research Associate
